Compare Western Alliance Bancorporation (WAL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Western Alliance Bancorporation vs Zoetis Inc — how do they compare? Western Alliance Bancorporation trades at $82.6 (market cap $8.89B), while Zoetis Inc trades at $73.7 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 3.5× Western Alliance Bancorporation's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| WAL | ZTS | |
|---|---|---|
Market Cap | $8.89B | $31.14B |
Sector | Financials | Health |
52-Week High | $96.08 | $156.76 |
52-Week Low | $66.70 | $71.91 |
Dividend Yield | 2.06% | 2.81% |
Enterprise Value | — | $38.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Western Alliance Bancorporation (WAL) trades at $82.62, up 2.66% today, with a neutral technical signal and bullish analyst sentiment. The stock shows strong fundamentals with a P/E of 9.2, net income margin of 25.43%, and recent earnings beats in Q4 2025 and Q1 2026. Recent developments include the launch of WA VenueX, a financial platform for digital assets, and recognition as Arizona's #1 bank by Forbes in 2026.
Outlook remains positive with a consensus price target of $93.86, implying 13.6% upside, supported by revenue growth and profitability. Risks include reliance on net interest income, competitive pressures, and macroeconomic sensitivity. Institutional activity shows mixed signals with some trimming positions, but overall analyst consensus is strongly bullish with 79% buy ratings.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
